Infusion Reaction in Hematology/Oncology
Clinical Pathways promote evidence based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by methodical review of available evidence and consensus among committee members.
Clinical Pathway:
Inclusion criteria:
- Hematology/Oncology patient presenting with an allergic reaction
Committee members involved in the development:
- Karen Lewing, MD | Hematology/Oncology/BMT | Committee chair
- Amanda August, PharmD | Oncology | Committee member
EBP Committee Members:
- Kathleen Berg, MD, FAAP | Hospital Medicine and Evidence Based Practice | Committee Member
- Jarrod Dusin, MS, RD, LD, CQHP | Evidence Based Practice | Committee Member
Publication dates:
- Revision date: 4/25/2023
- Next expected revision date: April 2026
If you have any questions regarding this content, or identify a broken link, please email evidencebasedpractice@cmh.edu.
These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.